Six Consultancy Reports, One Missing Layer: Why HCP Education Needs a Measurement Platform

Posted in Uncategorized

Six of the world’s biggest consultancies published AI surveys between late 2024 and late 2025. All six landed in the same place.

It is not the place their executive summaries start. Their executive summaries talk about adoption curves, agentic architectures, and enterprise transformation programmes. But if you read past the headline slides and into the data, the common finding is blunt: AI investment is outrunning AI value, and the reason is that companies are plugging AI into processes that were never designed around measurement.

That is the exact gap HCP education has been sitting inside for a decade.

What the 2025 data actually says

According to McKinsey’s State of AI 2025 report (published November 2025, surveyed June to July 2025, accessed 22 April 2026), 88% of organisations now regularly use AI in at least one business function. That is up from 78% the year before. Adoption is not the problem. The same report notes that roughly two-thirds of organisations remain in experimentation or piloting, suggesting that a majority are using AI without the operational infrastructure to evidence impact.

Deloitte’s State of AI in the Enterprise (wave surveyed August to September 2025, accessed 22 April 2026) puts a sharper number on it: only 34% of companies are truly reimagining their business around AI, while worker access to AI tools rose 50% in 2025. In other words, tools went everywhere; redesign went almost nowhere.

Bain’s Technology Report 2025 (accessed 22 April 2026) quantifies the penalty for stopping at tool-adoption: AI leaders that scale AI deliver 10 to 25% EBITDA gains, the laggards don’t.

Accenture’s Pulse of Change 2025 (accessed 22 April 2026) closes the loop with the starkest number of the four: only 32% of leaders report sustained, enterprise-wide AI impact, despite near-universal aspiration.

Four independent surveys. One finding. The gap between AI investment and AI value is the defining problem of 2025-26.

Why this matters in medical education specifically

Most HCP education programmes are still measured the way they were in 2015: attendance registers, completion rates, CPD certificates. That is the healthcare version of the same mistake the four consultancies are documenting across every sector, measuring activity, not outcome.

Pharma and biotech clients paying for HCP education are increasingly asking a different question. It is not ”did the HCP attend?” It is ”did the HCP do something different as a result?” That is Moore’s Level 5, behaviour change, and until very recently there was no automated way to capture it across a programme of 500 clinicians.

A platform that captures every HCP interaction, feeds that into a proof layer, and produces a distance-travelled measurement six weeks later is not a nice-to-have. It is the missing infrastructure layer those four consultancy reports have been pointing at, applied to the medical education use case.

Platform, not project

There is a second finding buried in the same reports. Bain’s Technology 2025 analysis notes that the companies extracting real AI value are those building platform infrastructure rather than running project-by-project pilots. That recommendation maps directly to how MedComms agencies and pharma medical affairs teams have historically run HCP education: one campaign at a time, one event at a time, with measurement bolted on retrospectively if at all.

A platform is different. A platform captures every HCP interaction in every programme, every year, and delivers a proof artefact unprompted. The unit of measurement is no longer the event. It is the HCP journey across the entire therapeutic area.

What to look for in a measurement layer

If you run an HCP education programme, or commission one, here is a practical checklist drawn from the four report themes:

1. Measurement designed in from day one, not bolted on. If the measurement layer is a post-event survey, it is not a platform. It is a questionnaire.
2. Persistent engagement between events. Drop-in / drop-out programmes cannot measure distance travelled because they do not observe the HCP long enough.
3. Automated follow-up at Moore’s Level 5. Behaviour change sits six weeks after the intervention. If the platform cannot re-engage the HCP at that window automatically, it is not measuring behaviour.
4. Proof artefact, not raw data dump. The deliverable to your pharma / biotech client is a report that evidences change, with citations. Not a CSV.
5. Infrastructure you can white-label. The agency owns the client relationship; the platform owns the measurement. If those get confused, the platform is competing with you instead of enabling you.

The opportunity window

Bain specifically identifies speed of redesign as the competitive variable for the next 18 to 24 months. In medical education terms: agencies and medical affairs teams that adopt a measurement platform in 2026 will be pitching proof to pharma procurement in 2027 while their competitors are still pitching slide decks. That window closes when measurement becomes table stakes. It is not closed yet.

Yoke Health was built for this gap. We are the measurement layer between your events, the persistent infrastructure that captures every HCP interaction, evidences distance travelled, and delivers the proof report your pharma client has been asking for and nobody has been able to deliver at scale.

Sources

: McKinsey. State of AI 2025. Published November 2025. (accessed 22 April 2026)
. Deloitte. State of AI in the Enterprise (Aug to Sep 2025 wave). (accessed 22 April 2026)
. Bain & Company. Technology Report 2025: State of the Art of Agentic AI Transformation. (accessed 22 April 2026)
. Accenture. Pulse of Change 2025. (accessed 22 April 2026)

Legal notice

Sources cited in this post are the intellectual property of their respective publishers. Quoted statistics and findings are reproduced for editorial commentary and analysis under fair-dealing provisions of the UK Copyright, Designs and Patents Act 1988. Accessed dates are provided inline above. Readers are encouraged to consult the original source reports for full context and the full quantitative dataset. Yoke Health is not affiliated with, endorsed by, or sponsored by McKinsey & Company, Deloitte, Bain & Company, or Accenture.